WO2006053150A3 - Pharmaceutical compositions for topical application on the treatment of age-related macular degeneration and ocular hypertension - Google Patents

Pharmaceutical compositions for topical application on the treatment of age-related macular degeneration and ocular hypertension Download PDF

Info

Publication number
WO2006053150A3
WO2006053150A3 PCT/US2005/040806 US2005040806W WO2006053150A3 WO 2006053150 A3 WO2006053150 A3 WO 2006053150A3 US 2005040806 W US2005040806 W US 2005040806W WO 2006053150 A3 WO2006053150 A3 WO 2006053150A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
age
macular degeneration
related macular
ocular hypertension
Prior art date
Application number
PCT/US2005/040806
Other languages
French (fr)
Other versions
WO2006053150A2 (en
WO2006053150B1 (en
Inventor
Mee Charles P R De C Du
Gene Barnett
Michael Coy
Original Assignee
Nascent Pharmaceuticals Inc
Mee Charles P R De C Du
Gene Barnett
Michael Coy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nascent Pharmaceuticals Inc, Mee Charles P R De C Du, Gene Barnett, Michael Coy filed Critical Nascent Pharmaceuticals Inc
Publication of WO2006053150A2 publication Critical patent/WO2006053150A2/en
Publication of WO2006053150A3 publication Critical patent/WO2006053150A3/en
Publication of WO2006053150B1 publication Critical patent/WO2006053150B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Abstract

A topically applied pharmaceutical composition for the prevention or treatment of age-related macular degeneration, ocular hypertension, glaucoma or any eye disease resulting from increase intraocular pressure, comprised of a solution of 17-β-estradiol suspended or dissolved in a vehicle, and the method of treatment using same.
PCT/US2005/040806 2004-11-12 2005-11-14 Pharmaceutical compositions for topical application on the treatment of age-related macular degeneration and ocular hypertension WO2006053150A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62688804P 2004-11-12 2004-11-12
US60/626,888 2004-11-12

Publications (3)

Publication Number Publication Date
WO2006053150A2 WO2006053150A2 (en) 2006-05-18
WO2006053150A3 true WO2006053150A3 (en) 2006-08-17
WO2006053150B1 WO2006053150B1 (en) 2006-10-26

Family

ID=36337224

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/040806 WO2006053150A2 (en) 2004-11-12 2005-11-14 Pharmaceutical compositions for topical application on the treatment of age-related macular degeneration and ocular hypertension

Country Status (1)

Country Link
WO (1) WO2006053150A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027988A2 (en) * 2006-08-31 2008-03-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation
CN115304657B (en) * 2022-07-07 2024-04-30 武汉工程大学 Preparation method and application of estradiol phosphate and salts thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029122A1 (en) * 1996-12-30 1998-07-09 Helmut Zander Use of active ingredients with oestrogenic effect for the prevention and treatment of macular degeneration
US6096733A (en) * 1998-12-10 2000-08-01 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US6172054B1 (en) * 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
US6852710B2 (en) * 2001-06-11 2005-02-08 Southwest Foundation For Biomedical Research 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
US20050261641A1 (en) * 2002-09-26 2005-11-24 Warchol Mark P Method for ophthalmic administration of medicament

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172054B1 (en) * 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
WO1998029122A1 (en) * 1996-12-30 1998-07-09 Helmut Zander Use of active ingredients with oestrogenic effect for the prevention and treatment of macular degeneration
US6096733A (en) * 1998-12-10 2000-08-01 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US6852710B2 (en) * 2001-06-11 2005-02-08 Southwest Foundation For Biomedical Research 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
US20050261641A1 (en) * 2002-09-26 2005-11-24 Warchol Mark P Method for ophthalmic administration of medicament

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ESPINOSA-HEIDMANN D. G.: "Gender and Estrogen Supplementation Increases Severity of Experimental Choroidal Neovascularization", EXPERIMENTAL EYE RESEARCH, vol. 80, no. 3, March 2005 (2005-03-01), pages 413 - 423, XP004753524 *

Also Published As

Publication number Publication date
WO2006053150A2 (en) 2006-05-18
WO2006053150B1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
WO2006116591A3 (en) Ophthalmic formulations comprising prednisolone acetate and tobramycin and uses thereof
MXPA03008401A (en) Combination of brimonidine and timolol for topical ophthalmic use.
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2006042329A8 (en) Crig polypeptide for prevention and treatment of complement-associated disorders
WO2006105403A3 (en) Treatment of eye disorders with sirtuin modulators
WO2006101839A3 (en) Enhanced bimatoprost ophthalmic solution
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
EP2052720A3 (en) Use of at least one hydroxylamine compound for the treatment of eye disease
WO2005084635A3 (en) Pharmaceutical ocular preparations suitable for the treatment of the ocular surface and related disorders/diseases
WO2007044668A3 (en) Compstatin and analogs thereof for eye disorders
WO2007038687A3 (en) Ocular administration of immunosuppressive agents
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007011874A3 (en) Formulation and method for administration of ophthalmologically active agents
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
WO2003047513A3 (en) Method for treating ocular hypertension
WO2004112836A3 (en) Ophthalmic compositions containing a synergistic combination of two polymers
WO2008140052A1 (en) Prophylactic or therapeutic agent for posterior ocular disease comprising ropinirole or salt thereof as active ingredient
WO2006062731A8 (en) Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007046083A3 (en) Compositions for treatment of eye diseases
WO2010028088A3 (en) Sulfur-linked compounds for treating opthalmic diseases and disorders
WO2002040056A8 (en) Carrageenan viscoelastics for ocular surgery
CA2505086A1 (en) Ophthalmic compositions for treating ocular hypertension
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase

Ref document number: 05848471

Country of ref document: EP

Kind code of ref document: A2